This is the authors' abstract. We don't add key points for this paper.
Genetic focal segmental glomerulosclerosis (FSGS) is traditionally thought not to recur following kidney transplantation (KT). Whereas recent evidence shows recurrences in NPHS2 and CRB2 mutations, we report the first documented recurrence of genetic FSGS associated with a COL4A4 mutation. An 18-year-old female with childhood-onset FSGS progressing to end-stage kidney disease (ESKD) underwent a living-related KT from her asymptomatic, carrier brother. Genetic analysis revealed a homozygous COL4A4 c.2242G>T (p.Gly748Cys) mutation with no family history of Alport syndrome. Two months post-KT, she developed severe nephrotic syndrome (proteinuria: 26 g/d) and allograft dysfunction (creatinine: 3.4 mg/dl). An initial biopsy indicated minimal change disease. Intensive rescue therapy, including high-dose corticosteroids, 7 cycles of plasmapheresis, and rituximab, normalized her creatinine to 0.9 mg/dl, but heavy proteinuria persisted. A 17-month follow-up biopsy confirmed recurrent FSGS. Obinutuzumab was initiated for the refractory nephrotic syndrome, successfully reducing proteinuria to a stable 2.5 to 3.0 g/d. However, this intensified immunosuppression was complicated by infections, cytomegalovirus viremia, and pancytopenia. This case provides the first evidence that COL4A4 -associated genetic FSGS can recur posttransplantation, challenging existing paradigms and highlighting the need to investigate underlying mechanisms and alternative rescue therapies such as obinutuzumab.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Berkkan et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: